Ivonescimab + chemotherapy improves progression-free survival in patients with EGFR+ NSCLC
Credit: Anna Tarazevich from Pexels Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged ...